Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.44 |
| ▸ | SPR | P35270 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | FPR1 | P21462 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3094963 | 0.82 | TSHR (0.49) | TSHRSIRT3TDP1HSD11B1ALDH1A1 | |
| SCHEMBL16098855 | 0.79 | HPGD (0.70) | HPGDTSHRHSD11B1NPC1ALDH1A1 | |
| SCHEMBL26666375 | 0.77 | POLB (0.61) | HPGDTSHRPOLBHSD11B1NPC1 | |
| SCHEMBL3610975 | 0.76 | HPGD (0.43) | HPGDTSHRPOLBHSD11B1NPC1 | |
| SCHEMBL14907222 | 0.76 | SIRT3 (0.61) | SIRT3TDP1 | |
| SCHEMBL4154297 | 0.75 | HPGD (0.54) | HPGDTSHRPOLBHSD11B1NPC1 | |
| SCHEMBL4153903 | 0.75 | ALDH1A1 (0.62) | HPGDTSHRPOLBHSD11B1NPC1 | |
| SCHEMBL5647289 | 0.75 | HPGD (0.56) | HPGDTSHRPOLBHSD11B1NPC1 | |
| SCHEMBL15563693 | 0.75 | SIRT3 (0.59) | SIRT3TDP1 | |
| SCHEMBL9001760 | 0.75 | TSHR (0.79) | HPGDTSHRPOLBHSD11B1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8084470-B2 | Substituted nicotinamide compounds and uses thereof | GRUENENTHAL GMBH (DE) | 2011-12-27 | — | — | US | disclosed |
| US-20090076086-A1 | SUBSTITUTED NICOTINAMIDE COMPOUNDS AND USES THEREOF | GRUENENTHAL GMBH (DE) | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076086-A1 | SUBSTITUTED NICOTINAMIDE COMPOUNDS AND USES THEREOF | NNT, NAMPT, NADK | HPGD 11/4885TSHR 4680/4885POLB 1752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.